HUTCHMED (China) (HMDCF) Accounts Payables (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Accounts Payables came in at $33.6 million in Q2 2026, down 23.05% year-over-year from $43.7 million in Q2 2025, and down 26.11% quarter-over-quarter from $45.5 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Accounts Payables (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Accounts Payables for 12 consecutive years, with $33.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Accounts Payables fell 23.05% year-over-year to $33.6 million in Q2 2026; TTM through Jun 2026 was $33.6 million, a 23.05% decrease from a year earlier, with the FY2025 full-year figure at $45.5 million, changed N/A from the prior year.
- Accounts Payables was $33.6 million for Q2 2026 at HUTCHMED (China), down from $45.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $71.1 million in Q4 2022 and troughed at $33.6 million in Q2 2026.
- A 5-year average of $49.0 million and a median of $45.5 million in 2025 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables surged 78.88% in 2022 and retreated 23.05% in 2026, its largest moves.
- Over 5 years, Accounts Payables stood at $71.1 million in 2022, then declined by 23.26% to $54.6 million in 2023, then fell by 20.48% to $43.4 million in 2024, then advanced by 4.92% to $45.5 million in 2025, then fell by 26.11% to $33.6 million in 2026.
- The last three Accounts Payables figures came in at $33.6 million (Q2 2026), $45.5 million (Q4 2025), and $43.7 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | 25.08 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 33.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.65 Mn |
| Dec 31, 2025 | 45.53 Mn |
| Jun 30, 2025 | 43.73 Mn |
| Jun 30, 2024 | 43.40 Mn |
| Jun 30, 2023 | 54.58 Mn |
| Dec 31, 2022 | 71.12 Mn |
| Jun 30, 2022 | 51.01 Mn |
| Dec 31, 2021 | 41.18 Mn |
| Jun 30, 2021 | 28.51 Mn |
| Mar 31, 2021 | 28.64 Mn |
| Dec 31, 2020 | 31.61 Mn |
| Jun 30, 2020 | 25.87 Mn |
| Dec 31, 2019 | 23.96 Mn |
| Sep 30, 2019 | 23.03 Mn |
| Jun 30, 2019 | 26.15 Mn |
| Mar 31, 2019 | 30.76 Mn |
| Dec 31, 2018 | 25.63 Mn |
| Jun 30, 2018 | 19.31 Mn |
| Dec 31, 2017 | -11.17 Mn |
| Jun 30, 2017 | 27.26 Mn |